title: Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases.
authors.affiliation: a Cumming School of Medicine , Tom Baker Cancer Centre, University of Calgary , Calgary , Alberta , Canada ;
authors.forename: Raida
authors.initials: R
authors.lastname: Khwaja
authors.affiliation: a Cumming School of Medicine , Tom Baker Cancer Centre, University of Calgary , Calgary , Alberta , Canada ;
authors.forename: Andrew
authors.initials: A
authors.lastname: Daly
authors.affiliation: a Cumming School of Medicine , Tom Baker Cancer Centre, University of Calgary , Calgary , Alberta , Canada ;
authors.forename: Michael
authors.initials: M
authors.lastname: Wong
authors.affiliation: a Cumming School of Medicine , Tom Baker Cancer Centre, University of Calgary , Calgary , Alberta , Canada ;
authors.forename: Etienne
authors.initials: E
authors.lastname: Mahé
authors.affiliation: b Division of Hematology , Mayo Clinic , Rochester , MN , USA.
authors.forename: Sonia
authors.initials: S
authors.lastname: Cerquozzi
authors.affiliation: a Cumming School of Medicine , Tom Baker Cancer Centre, University of Calgary , Calgary , Alberta , Canada ;
authors.forename: Carolyn
authors.initials: C
authors.lastname: Owen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001374:Azacitidine / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000187:drug effects / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000473:pathology; D020360:Neoadjuvant Therapy; D016896:Treatment Outcome
chemical_list: D001374:Azacitidine